+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Systemic Lupus Erythematosus (Immunology) - Drugs in Development, 2021

  • PDF Icon

    Drug Pipelines

  • 1013 Pages
  • September 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5451326
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide, 'Systemic Lupus Erythematosus - Drugs In Development, 2021', provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape. Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights


This latest pipeline guide provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the latest news and press releases. The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 48, 34, 4, 81, 27 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 1, 1, 13 and 2 molecules, respectively.

The Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Systemic Lupus Erythematosus - Overview

Systemic Lupus Erythematosus - Therapeutics Development

Systemic Lupus Erythematosus - Therapeutics Assessment

Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development

Systemic Lupus Erythematosus - Drug Profiles

Systemic Lupus Erythematosus - Dormant Projects

Systemic Lupus Erythematosus - Discontinued Products

Systemic Lupus Erythematosus - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Systemic Lupus Erythematosus, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Abcentra LLC, 2021
  • Systemic Lupus Erythematosus - Pipeline by Accro BioScience (Suzhou) Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Akeso Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Alexion Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Alphamab Oncology, 2021
  • Systemic Lupus Erythematosus - Pipeline by Alpine Immune Sciences Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Aluda Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Amgen Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Ampio Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Annexon Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Apimeds Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Aprilbio Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by APT Therapeutics Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Aria Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, 2021
  • Systemic Lupus Erythematosus - Pipeline by Astellas Pharma Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by AstraZeneca Plc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Athos Therapeutics Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Avotres Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by BeiGene Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Beijing Mabworks Biotech Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by BellBrook Labs LLC, 2021
  • Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by BioAegis Therapeutics Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Biocon Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Biogen Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Biotest AG, 2021
  • Systemic Lupus Erythematosus - Pipeline by BioTherapeutics Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by BioTheryX Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Systemic Lupus Erythematosus - Pipeline by Boston Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Brickell Biotech Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, 2021
  • Systemic Lupus Erythematosus - Pipeline by Capricor Therapeutics Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Carna Biosciences Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by CellionBioMed Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Cells for Cells SA, 2021
  • Systemic Lupus Erythematosus - Pipeline by Centessa Pharmaceuticals Plc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Centivax Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by ChemoCentryx Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Chinook Therapeutics Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2021
  • Systemic Lupus Erythematosus - Pipeline by Citryll BV, 2021
  • Systemic Lupus Erythematosus - Pipeline by Corbus Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Corestem Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by CSPC Pharmaceutical Group Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Eledon Pharmaceuticals Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, 2021
  • Systemic Lupus Erythematosus - Pipeline by Epsilon-3 Bio Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Ergon Pharmaceuticals LLC, 2021
  • Systemic Lupus Erythematosus - Pipeline by Exinda Therapeutics LLC, 2021
  • Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Galapagos NV, 2021
  • Systemic Lupus Erythematosus - Pipeline by Genentech USA Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by Genesen Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by GenFleet Therapeutics (Shanghai) Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Genosco Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Genovax Srl, 2021
  • Systemic Lupus Erythematosus - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2021
  • Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, 2021
  • Systemic Lupus Erythematosus - Pipeline by Good T Cells Inc, 2021
  • Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, 2021
  • Systemic Lupus Erythematosus - Dormant Projects, 2021
  • Systemic Lupus Erythematosus - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Systemic Lupus Erythematosus, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc
  • Abcentra LLC
  • Accro BioScience (Suzhou) Co Ltd
  • Akeso Inc
  • Alexion Pharmaceuticals Inc
  • Alphamab Oncology
  • Alpine Immune Sciences Inc
  • Aluda Pharmaceuticals Inc
  • Amgen Inc
  • Ampio Pharmaceuticals Inc
  • Annexon Inc
  • Apellis Pharmaceuticals Inc
  • Apimeds Inc
  • Aprilbio Co Ltd
  • APT Therapeutics Inc
  • Aria Pharmaceuticals Inc
  • Asahi Kasei Pharma Corp
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Athos Therapeutics Inc
  • Aurinia Pharmaceuticals Inc
  • Avotres Inc
  • BeiGene Ltd
  • Beijing Mabworks Biotech Co Ltd
  • BellBrook Labs LLC
  • Bio-Path Holdings Inc
  • BioAegis Therapeutics Inc
  • Biocon Ltd
  • Biogen Inc
  • Biotest AG
  • BioTherapeutics Inc
  • BioTheryX Inc
  • Boehringer Ingelheim International GmbH
  • Boston Pharmaceuticals Inc
  • Brickell Biotech Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Carna Biosciences Inc
  • CellionBioMed Inc
  • Cells for Cells SA
  • Centessa Pharmaceuticals Plc
  • Centivax Inc
  • ChemoCentryx Inc
  • Chinook Therapeutics Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Citryll BV
  • Corbus Pharmaceuticals Inc
  • Corestem Inc
  • CSPC Pharmaceutical Group Ltd
  • CuraVac Inc
  • Daiichi Sankyo Co Ltd
  • Domainex Ltd
  • Eisai Co Ltd
  • Eledon Pharmaceuticals Inc
  • Eli Lilly and Co
  • Epsilon-3 Bio Ltd
  • Ergon Pharmaceuticals LLC
  • Exinda Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Genentech USA Inc
  • GeneScience Pharmaceuticals Co Ltd
  • Genesen Co Ltd
  • GenFleet Therapeutics (Shanghai) Inc
  • Genosco Inc
  • Genovax Srl
  • Genrix (Shanghai) Biopharmaceutical Co Ltd
  • GlaxoSmithKline Plc
  • Good T Cells Inc
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HemoGenyx Pharmaceuticals Plc
  • Horizon Therapeutics Plc
  • Huabo Biopharm (Shanghai) Co Ltd
  • iCELL Biotechnology Co Ltd
  • Ichnos Sciences Inc
  • Idorsia Pharmaceutical Ltd
  • IL-2Rx Inc
  • Iltoo Pharma
  • Immplacate
  • Immune Modulation Inc
  • Immungenetics AG
  • ImmunoBiome Inc
  • ImmunoQure AG
  • Immunwork Inc
  • Immupharma Plc
  • InnoCare Pharma Ltd
  • Innovimmune Biotherapeutics Inc
  • iSD Immunotech ApS
  • JAMM Therapeutics Ltd
  • Janus Biotherapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • JiangSu Qyuns Therapeutics Co Ltd
  • Jiangsu Simcere Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Jubilant Therapeutics Inc
  • Jura Bio Inc
  • Kangpu Biopharmaceuticals Ltd
  • Karyopharm Therapeutics Inc
  • Kezar Life Sciences Inc
  • Kiniksa Pharmaceuticals Ltd
  • Kyowa Kirin Co Ltd
  • Lead Discovery Center GmbH
  • MedAnnex Ltd
  • MENTRIK Biotech LLC
  • Merck & Co Inc
  • Merck KGaA
  • MorphoSys AG
  • Nanjing Aimeifei Biomedical Technology Co Ltd
  • Nektar Therapeutics
  • Neovacs SA
  • Neutrolis Inc
  • Novartis AG
  • Octagon Therapeutics Inc
  • Octapharma AG
  • Omeros Corp
  • Pfizer Inc
  • Pharchoice Therapeutics Inc
  • ProNoxis AB
  • Provention Bio Inc
  • Ra Pharmaceuticals Inc
  • ReAlta Life Sciences Inc
  • Regen BioPharma Inc
  • Reistone Biopharma Co Ltd
  • Resolve Therapeutics LLC
  • Rheos Medicines Inc
  • Rongchang Pharmaceuticals Ltd
  • Sanofi
  • Sareum Holdings Plc
  • Sarkana Pharma Inc
  • SBI Biotech Co Ltd
  • Sengenics Corp Pte Ltd
  • Serenity Bioworks Inc
  • Shanghai GeneChem Co Ltd
  • Shanghai Jiyu Pharmaceutical Technology Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai YaKe Biotechnology Co Ltd
  • Shenzhen Chipscreen Biosciences Co Ltd
  • SinoMab Bioscience Ltd
  • Slate Bio Inc
  • Sorrento Therapeutics Inc
  • Steel Therapeutics Inc
  • StingInn LLC
  • Suzhou Sinovent Pharmaceuticals Co Ltd
  • Swedish Orphan Biovitrum AB
  • SynAct Pharma AB
  • Takeda Pharmaceutical Co Ltd
  • Tasly Biopharmaceuticals Co Ltd
  • Technoderma Medicines Inc
  • TherapyX Inc
  • Tonix Pharmaceuticals Holding Corp
  • Transcenta Holding Ltd
  • UCB SA
  • Vera Therapeutics Inc
  • Viracta Therapeutics Inc
  • Visterra Inc
  • Xencor Inc
  • XTL Biopharmaceuticals Ltd
  • Zylo Therapeutics LLC
  • ZyVersa Therapeutics Inc